Skinvisible, Inc. (SKVI) Formulation Submitted to European Union for Orphan Drug Designation
2/23/2012 9:23:12 AM
LAS VEGAS, Feb. 23, 2012 (GLOBE NEWSWIRE) -- Skinvisible, Inc. (OTCQB:SKVI), a developer of topical and transdermal formulations using its patented Invisicare technology, today announced it has submitted an Orphan Drug Designation application to the European Medicines Agency (EMA) for its proprietary formulation to treat Netherton Syndrome. Furthermore, Skinvisible has received notice that the application has been validated by the EMA and has begun the review process by the EMA's Committee for Orphan Medicinal Products (COMP). In conjunction with this application, Skinvisible has submitted a patent application for the formulation.